Our Pricing

Wegovy Starter Dose UK: Safe Initiation Protocol

Published on: June 03, 2026

Understanding the wegovy starter dose UK protocol is essential for safe, effective treatment. At Cured Pharmacy, our UK-registered clinical team guides patients through the evidence-based titration schedule, starting at 0.25mg weekly and gradually increasing over 16-20 weeks to minimise side effects whilst optimising weight loss outcomes [1].

Why Wegovy Uses a Starter Dose Protocol

Wegovy (semaglutide 2.4mg) requires gradual dose escalation because sudden exposure to higher doses significantly increases gastrointestinal side effects. The starter dose of 0.25mg weekly allows your body to adapt to semaglutide's effects on gastric emptying and appetite regulation [1].

Clinical trials demonstrated that patients following the structured titration schedule experienced 30-40% fewer discontinuations due to nausea and vomiting compared to faster escalation protocols [2]. This gradual approach, approved by the MHRA, balances tolerability with clinical efficacy.

The 0.25mg starter dose contains enough semaglutide to begin metabolic adaptation without overwhelming the GI system. Most patients report minimal side effects at this initial dose, with symptoms typically emerging only as doses increase beyond 0.5mg weekly.

Complete Wegovy Dosing Schedule UK

The standard Wegovy titration follows a five-stage protocol over 16-20 weeks. Each dose is maintained for at least four weeks before escalation, allowing your body to adjust and side effects to resolve [1].

Weeks 1-4: 0.25mg once weekly. This starter dose initiates GLP-1 receptor activation with minimal side effects. Most patients experience mild appetite reduction but limited weight loss during this phase.

Weeks 5-8: 0.5mg once weekly. Appetite suppression becomes more noticeable. Some patients report mild nausea, typically resolving within 2-3 days of each injection.

Weeks 9-12: 1.0mg once weekly. Weight loss accelerates during this phase. Gastrointestinal side effects peak here for most patients, requiring careful dietary management.

Weeks 13-16: 1.7mg once weekly. Clinical effects strengthen whilst side effects often diminish as tolerance develops. Average weight loss reaches 8-12% of baseline body weight by this stage [2].

Week 17 onwards: 2.4mg once weekly (maintenance dose). This therapeutic dose produced an average 14.9% body weight reduction over 68 weeks in the STEP 1 trial [2]. Your UK prescriber may adjust timing if side effects require slower escalation.

When to Delay Dose Escalation

If you experience persistent nausea, vomiting more than twice weekly, or severe gastrointestinal symptoms, remain at your current dose for an additional 4 weeks. The titration schedule is a guideline, not a rigid requirement — patient tolerance always takes priority.

Our superintendent pharmacist Tarun Kumar advises that approximately 15-20% of patients require extended titration periods. This does not reduce long-term efficacy; slower escalation often improves treatment adherence and final outcomes.

Managing Side Effects During Wegovy Starter Dose

Nausea is the most common side effect during Wegovy initiation, affecting approximately 44% of patients in clinical trials [2]. It typically peaks 2-3 days post-injection and resolves within 5-7 days as your body adapts.

Practical management strategies include eating smaller, more frequent meals rather than three large meals daily. Avoid high-fat, greasy, or spicy foods during the first 72 hours after each injection. Stay well-hydrated, aiming for 2-3 litres of water daily to prevent constipation, another common side effect.

If nausea persists beyond one week or prevents normal eating, contact your prescriber. Anti-nausea medications like domperidone or cyclizine can be prescribed short-term whilst your body adjusts. Never escalate to the next dose whilst experiencing unresolved side effects from your current dose.

Red Flag Symptoms Requiring Medical Attention

Seek immediate medical advice if you experience severe abdominal pain (especially upper right abdomen), persistent vomiting preventing fluid intake, visual changes, or signs of pancreatitis including radiating back pain with nausea. These occur in less than 1% of patients but require prompt assessment [1].

Hypoglycaemia (low blood sugar) is rare with Wegovy alone but can occur if you're also taking other diabetes medications. Symptoms include trembling, sweating, confusion, and rapid heartbeat. Your prescriber will adjust any concurrent medications during your assessment.

What to Expect: Wegovy Starter Dose Results

Weight loss during the 0.25mg starter dose is typically modest — most patients lose 1-3% of body weight over the first four weeks. This is expected and appropriate; the starter dose prioritises safety and tolerability over rapid weight reduction [2].

Appetite changes often appear before measurable weight loss. Many patients report feeling satisfied with smaller portions and reduced food cravings within 7-10 days of the first injection. This subjective response is a positive indicator that semaglutide is engaging GLP-1 receptors effectively.

By week 16-20, when reaching the 2.4mg maintenance dose, average weight loss reaches 10-15% of baseline body weight. The STEP clinical programme demonstrated that patients who completed the full titration schedule achieved significantly better outcomes than those who escalated too quickly and discontinued due to side effects [2].

Individual responses vary considerably. Factors including baseline BMI, dietary adherence, physical activity levels, and metabolic health all influence results. Your UK prescriber will monitor progress and adjust the treatment plan accordingly.

Wegovy Injection Technique for Starter Dose

Wegovy pens are pre-filled, single-use devices designed for subcutaneous injection into the abdomen, thigh, or upper arm. Rotate injection sites weekly to prevent lipohypertrophy (fatty lumps under the skin) which can impair absorption.

Before injecting, allow the pen to reach room temperature for 30 minutes — cold injections cause more discomfort. Clean the injection site with an alcohol wipe and let it dry completely. Remove the pen cap, place the pen firmly against your skin at a 90-degree angle, and press the dose button until you hear a click. Hold for 6 seconds to ensure full dose delivery.

Inject Wegovy on the same day each week, but the time of day doesn't matter. If you miss a dose and it's been less than 5 days, inject as soon as you remember. If more than 5 days have passed, skip that dose and resume your regular schedule. Never inject two doses within 72 hours.

Storage and Disposal Requirements

Store unused Wegovy pens in the refrigerator at 2-8°C. Once in use, pens can be kept at room temperature (below 30°C) for up to 28 days. Never freeze Wegovy; frozen pens must be discarded even if later thawed.

Dispose of used pens in a sharps container, available free from most UK pharmacies or your local council. Never throw pens in household waste or recycling bins. Cured Pharmacy can provide guidance on local sharps disposal services when you place your order.

Getting Wegovy Starter Dose from Cured Pharmacy

Wegovy is available at Cured Pharmacy from £79.00, with transparent upfront pricing displayed before your clinical consultation. All patients require assessment by a UK-registered prescriber to ensure Wegovy is clinically appropriate and safe for your individual circumstances.

Our online consultation takes under 3 minutes and covers your medical history, current medications, weight loss goals, and any contraindications. Your responses are reviewed by our UK clinical team, led by superintendent pharmacist Tarun Kumar (GPhC 2233073), who will determine your suitability for Wegovy starter dose treatment.

If approved, your prescription is dispensed from our UK-registered pharmacy (GPhC 9012511) and delivered in discreet packaging, typically within 2-3 working days. Your prescription will begin with the 0.25mg starter dose, with subsequent doses supplied according to the titration schedule.

We provide ongoing clinical support throughout your treatment journey. If you need to adjust your titration schedule, discuss side effects, or have questions about injection technique, our team is available by phone on (+44) 116 4646009 during business hours.

Scientific References

1. Novo Nordisk. (2023). Wegovy 0.25 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
4. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
5. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine and must be prescribed following an online consultation with a UK-registered clinician.